Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketoprofen + capsaicin is a combination therapy consisting of a ketoprofen transdermal patch and topical capsaicin, primarily investigated for the self-management of myofascial pain syndrome (MPS). Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID) that acts by inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of pro-inflammatory prostaglandins. Capsaicin is a potent agonist of the transient receptor potential vanilloid 1 (TRPV1) receptor; its therapeutic effect is derived from the initial stimulation followed by a long-lasting desensitization of nociceptive nerve fibers. This dual-action approach aims to provide both anti-inflammatory relief and neurogenic pain modulation. The combination was evaluated in a pilot study by Yonsei University as a self-applicable modality for managing upper trapezius myofascial pain, showing improvements in pain scores and cervical range of motion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketoprofen + capsaicin.